Stoke Therapeutics, Inc. Common Stock (STOK)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 170
- Market Cap
- $1.9B
About Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
SentiSense also tracks daily options readings for Stoke Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Stoke Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.